CCND1 and glioblastoma: NES contributes to cytoskeletal dynamics and motility and has been clinically associated with poor prognosis [22], while CCND1 regulates the G1/S transition and has been implicated in therapy resistance, mesenchymal transition, and increased motility in GBM [23,24].